Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion type Assertion NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_head.
- NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion description "[EGFR and FCGR3A germline polymorphisms are associated with PFS in KRAS wild-type mCRC patients treated with cetuximab, bevacizumab and chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_provenance.
- NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion evidence source_evidence_literature NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_provenance.
- NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion SIO_000772 20418097 NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_provenance.
- NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion wasDerivedFrom gad-20150221 NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_provenance.
- NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_assertion wasGeneratedBy ECO_0000203 NP140017.RApROE84tY_02RCRlsp15lS_SyCLby5RjuWSzna3SAL_4130_provenance.